oral semaglutide novo US regulators approve Wegovy pill, first medication to treat obesity | US healthcare Wegovy media kit

The weight loss with semaglutide was consistent over the first 65 weeks and maintained throughout the entire study, with an average weight loss of 11.7% reported by the end

For diabetics, this can cause Hypoglycemia (dangerously low blood sugar), leading to dizziness, confusion, or fainting

These therapies, primarily administered as subcutaneous injectables for ease of at-home use, act by mimicking the native GLP1 hormone, enhancing glucose-dependent insulin secretion, suppressing glucagon release, lowering HbA1c levels, and promoting weight loss - all while carrying a minimal risk of hypoglycemia when used alone

By working directly on the brains hunger centers, slowing digestion, and interacting with the bodys reward system, GLP-1 helps individuals achieve and sustain significant weight loss

It also slows gastric emptying and reduces glucose production by the liver

Zepbound dose strengths include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg